Please login to the form below

Not currently logged in
Email:
Password:

Breast cancer drug showing strong performance

Roche has revealed that studies into ibandronic acid have shown it could help prevent crippling bone breaks and injuries in women taking anastrozole, a crucial breast cancer treatment
Roche has revealed that studies into ibandronic acid have shown it could help prevent crippling bone breaks and injuries in women taking anastrozole, a crucial breast cancer treatment.

Anastrolzole is an efficacious and well-tolerated therapy option for breast cancer but use of it is linked with a reduction in bone mineral density (BMD), which raises the risk of fractures. Data from studies were presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO).

"Anastrolzole is an important therapy for breast cancer patients but we clearly want to reduce their risk of declining bone density and resultant fractures and osteoporosis," said Dr Jim Lester, lead study investigator at the Cancer Research Centre, Weston Park Hospital in Sheffield. "The results are very reassuring as they show that the strengthening effect of monthly ibandronate at the spine and at the hip is maintained after two years."

The Aribon study assessed the impact of ibandronic acid on post-menopausal patients with early breast cancer taking anastrolzole. Results indicate that, taken as a one-a-month dose, ibandronic acid significantly increases BMD and prevents bone loss in patients with osteopenic, which is a mild thinning of the bones.

Lester said that the treatment option "offers a promising solution for physicians prescribing anastrolzole to breast cancer patients."

3rd June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics